<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383500</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-01671</org_study_id>
    <secondary_id>95970</secondary_id>
    <secondary_id>BRSNSTU0007</secondary_id>
    <nct_id>NCT00383500</nct_id>
  </id_info>
  <brief_title>Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status</brief_title>
  <official_title>To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of usual treatments for lymphedema [massage and elastic
      compression sleeve, instituted at-risk and before the development of swelling (lymphedema)],
      compared to the use of a newly-marketed device, the Flexitouch, which electronically
      simulates the effect of massage upon lymph flow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current investigation is designed to prospectively evaluate the potential for simple,
      effective lymphedema prophylaxis in breast cancer survivors who show early evidence of
      high-risk status. There is growing evidence that the mechanisms of lymphatic repair after
      injury are mediated through lymphatic flow. Accordingly, this study assess if physical
      measures designed to prophylactically augment lymphatic flow after surgical interventions for
      breast cancer (eg, Flexitouch and manual lymphatic massage) will reduce the incidence of
      lymphatic stagnation, assessed as incidence of lymphedema, when compared to patients who
      receive conventional &quot;watch and wait&quot; interventions (observation).

      The specific aims of the study are

        1. to prospectively assess the presence of newly developing lymphedema in each study
           subgroup through serial assessment of segmental interstitial fluid content by multiple
           frequency bioimpedance

        2. to evaluate the preventive interventions in a prospective, randomized fashion,
           contrasting the responses of equivalent numbers of patients randomized to 2 experimental
           arms and the control arm of the study

        3. to correlate the bioimpedance findings with concurrently derived, serial assessments of
           limb volume

      Recent advances in the medical understanding of the biological processes of lymphatic
      development and repair suggest that these mechanisms may be able to be manipulated to enhance
      the regenerative responses in the lymphatic vasculature following injury. Breast
      cancer-associated lymphedema is a model of such an acquired form of lymphatic vasculature
      insufficiency. Clinically, this poses a substantial clinical problem. It is estimated at
      1woman in 4 who survives a breast cancer intervention will develop lymphedema, often
      progressively. The appearance of lymphedema has documented adverse effects on physical and
      psychologically well-being. New insights into lymphatic repair suggest that such mechanisms
      can be employed in a prophylactic fashion to forestall or eliminate the development of
      lymphedema. This proposal investigates this hypothesis in a prospective fashion, using a
      randomized trial design in 80 patients enrolled at the time of breast cancer surgery. If the
      investigation documents a beneficial effect of preventive measures, it could have a profound
      impact on subsequent breast cancer care. These measures are simple and cost-effective and,
      could help to eliminate the impact of a substantial detractor to the improved longevity and
      health that breast cancer survivors otherwise may expect to enjoy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy</measure>
    <time_frame>36 months</time_frame>
    <description>Successful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Lymphedema (Newly-developing)</measure>
    <time_frame>3 years of semi-annual follow-up</time_frame>
    <description>Incidence of newly-developing lymphedema for each study cohort, as detected by serial multiple frequency bioimpedance spectroscopy scans for increased interstitial fluid within regional tissues.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Lymphedema</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Flexitouch device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual Lymphatic Drainage (MLD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Control (no intervention)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group, no intervention. No Flexitouch or manual massage therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flexitouch</intervention_name>
    <description>A standard of care intermittent pneumatic compression device (aka, lymphedema pump)</description>
    <arm_group_label>Flexitouch device</arm_group_label>
    <other_name>Tactile Systems Technology, Inc.</other_name>
    <other_name>Biocompression</other_name>
    <other_name>Lymphatic massage therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Class 1 compression garment</intervention_name>
    <description>Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).</description>
    <arm_group_label>Manual Lymphatic Drainage (MLD)</arm_group_label>
    <other_name>Manual lymphatic drainage</other_name>
    <other_name>Lymphatic massage therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral breast cancer

          -  Scheduled to undergo breast surgery and axillary lymph node dissection, with or
             without breast conserving techniques.

          -  Referred to the surgeons of the Stanford University Breast Cancer Program

          -  Capacity to provide informed consent.

          -  All experimental protocols will be reviewed and approved by the Stanford Institutional
             Review Board for the Protection of Human Subjects.

        Exclusion Criteria:

          -  Other serious systemic illness (renal failure, hepatic dysfunction, congestive heart
             failure, neurological or psychological impairment) that would confound the study or
             impair the patients' ability to participate.

          -  Recurrent breast cancer or other forms of pre-existing lymphedema.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley G Rockson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>February 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2017</results_first_posted>
  <last_update_submitted>February 11, 2017</last_update_submitted>
  <last_update_submitted_qc>February 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Stanley Rockson</investigator_full_name>
    <investigator_title>Professor of Lymphatic Research and Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided at this time.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment commenced in May 2005 and concluded 13 March 2012. Subjects were recruited from the medical clinics and Stanford University Hospital and Clinics.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Flexitouch Device</title>
          <description>Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)</description>
        </group>
        <group group_id="P2">
          <title>Manual Lymphatic Drainage (MLD)</title>
          <description>Lymphedema management via self-administered manual lymphatic massage therapy</description>
        </group>
        <group group_id="P3">
          <title>No Intervention Control</title>
          <description>No intervention observational control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I</title>
          <description>This group of patients will receive the device.</description>
        </group>
        <group group_id="B2">
          <title>Group II</title>
          <description>This group of patients will receive prophylactic MLD</description>
        </group>
        <group group_id="B3">
          <title>Group III</title>
          <description>This is the control group; they will receive no treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy</title>
        <description>Successful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups</description>
        <time_frame>36 months</time_frame>
        <population>All enrolled patients in the trial who did not withdraw or were lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Device</title>
            <description>Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)</description>
          </group>
          <group group_id="O2">
            <title>Manual Lymphatic Drainage (MLD)</title>
            <description>Lymphedema management via self-administered manual lymphatic drainage therapy</description>
          </group>
          <group group_id="O3">
            <title>No Intervention Control</title>
            <description>No intervention observational control</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy</title>
          <description>Successful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups</description>
          <population>All enrolled patients in the trial who did not withdraw or were lost to follow-up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Lymphedema (Newly-developing)</title>
        <description>Incidence of newly-developing lymphedema for each study cohort, as detected by serial multiple frequency bioimpedance spectroscopy scans for increased interstitial fluid within regional tissues.</description>
        <time_frame>3 years of semi-annual follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexitouch Device</title>
            <description>Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)</description>
          </group>
          <group group_id="O2">
            <title>Manual Lymphatic Drainage (MLD)</title>
            <description>Lymphedema management via self-administered manual lymphatic massage therapy</description>
          </group>
          <group group_id="O3">
            <title>No Intervention Control</title>
            <description>No intervention observational control</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Lymphedema (Newly-developing)</title>
          <description>Incidence of newly-developing lymphedema for each study cohort, as detected by serial multiple frequency bioimpedance spectroscopy scans for increased interstitial fluid within regional tissues.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flexitouch Device</title>
          <description>Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)</description>
        </group>
        <group group_id="E2">
          <title>Manual Lymphatic Drainage (MLD)</title>
          <description>Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment.</description>
        </group>
        <group group_id="E3">
          <title>Observational Control (no Intervention)</title>
          <description>Control group, no intervention. No Flexitouch or manual massage therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stanley G. Rockson</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-725-7571</phone>
      <email>rockson@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

